TICKERNERD
Menu
OSTXOSTXHealthcare · Biotechnology

OSTX Stock Forecast: OS Therapies, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$1.68
−7.69% on the day

The 4 Wall Street analysts covering OS Therapies, Inc. hold a median 12-month price target of $7.5 — +346.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 35 of 100 as at 11 Sept 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$78.5M
Ticker Nerd rank
35 / 100
Median analyst target
$7.50
Analysts covering
4
Revenue$0.0
Operating income−$8.6M
Net income−$8.6M
Free cash flow−$5.5M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−7.7%
1M
+5.0%
YTD
+20.0%
1Y
−27.3%
From 52W high
−27.3%
From 52W low
+44.8%
$1.16
$2.31
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

OSTX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores OS Therapies, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 11 Sept 2026
35 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
82
Size
78
Volatility
61
Value
55
Revisions
41
Momentum
40
Issuance
31
Growth
23
Quality
11

Accruals (82): Reported profit is backed by cash, and the company is not expanding recklessly.

Quality (11): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

OSTX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on OSTX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00$10.00$12.00$14.00Oct 25Jan 26Apr 26Jul 26OSTXHigh $13.00Median $7.50Low $6.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says4 analysts
4 Buy0 Hold0 Sell
Low $6.00Median $7.50High $13.00

The green dot is the last close — the median target sits +346.4% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
9 July 2026Roth CapitalInitiatesBuy—
19 May 2026Lake StreetMaintainsBuy—
30 Apr 2026D. Boral CapitalMaintainsBuy—
8 Apr 2026D. Boral CapitalMaintainsBuy—
27 Mar 2026D. Boral CapitalMaintainsBuy—
9 Mar 2026D. Boral CapitalMaintainsBuy—
5 Feb 2026D. Boral CapitalMaintainsBuy—
5 Jan 2026D. Boral CapitalMaintainsBuy—
15 Dec 2025D. Boral CapitalMaintainsBuy—
9 Dec 2025D. Boral CapitalMaintainsBuy—
5 Dec 2025D. Boral CapitalMaintainsBuy—
21 Nov 2025D. Boral CapitalMaintainsBuy—
18 Nov 2025Lake StreetMaintainsBuy—
17 Nov 2025D. Boral CapitalMaintainsBuy—
10 Oct 2025D. Boral CapitalMaintainsBuy—
30 Sept 2025D. Boral CapitalMaintainsBuy—
12 Sept 2025D. Boral CapitalMaintainsBuy—
2 Sept 2025D. Boral CapitalMaintainsBuy—
27 Aug 2025D. Boral CapitalMaintainsBuy—
20 Aug 2025D. Boral CapitalMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. OSTX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

OSTX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, OS Therapies, Inc. returned −27.3% against +17.5% for the S&P 500, dividends included.

OSTX vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120Oct 25Jan 26Apr 26Jul 26OSTXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

OSTX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

OS Therapies, Inc. (OSTX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−1.7×

Cheaper than 84% of US stocks

Price / sales
—
Price / book
−6.2×

Cheaper than 97% of US stocks

EV / EBITDA
−2.3×

Cheaper than 73% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
471.7%

Higher than 99% of US stocks

Return on assets
−232.7%

Higher than 1% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

OS Therapies, Inc. (OSTX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • OS Therapies, Inc. has a market value of $78.5M and an enterprise value of $84.8M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$39.4M.

  • Free cash flow in the twelve months to 30 June 2026: −$18.5M.

  • Shares outstanding: 45.3M.

  • Trailing P/E: −1.7×; forward P/E: 4.8× — the forward figure prices analyst consensus estimates, not reported earnings.

  • OS Therapies, Inc. employs 4 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 11 Sept 2026

Data provided by Twelve Data

Peers

OSTX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
OSTXOS Therapies, Inc.$78.5M
35
GANXGain Therapeutics, Inc.$73.9M
31
IBIOiBio, Inc.$73.3M
26
CINGCingulate, Inc.$73.0M
35
BSEMBioStem Technologies, Inc.$76.9M
54
PLRXPliant Therapeutics, Inc.$72.4M
65
YARWYarrow Bioscience, Inc.$72.1M
53

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own OS Therapies, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest OSTX news & analysis

OS Therapies Achieves Statistically Significant Benefit for OST-HER2-Treated Patients in Interim 3-Year Overall Survival Analysis of Phase 2b Pulmonary Metastatic Osteosarcoma Trial

Newsfile Corp · 8 Sept 2026positive

OS Therapies reported interim 3-year overall survival data from its Phase 2b pulmonary metastatic osteosarcoma trial, showing a 71.2% 3-year overall survival rate for OST-HER2-treated patients versus a 45.8% comparable combined historical control (p = 0.002). The company also received $3.15 million in VAT refunds into OS Therapies UK, Ltd., and noted that two remaining patients have monitoring visits scheduled for September and early October 2026.

Why it matters — OSTX watchers would care because the statistically significant overall survival improvement versus historical controls suggests the investigational treatment is performing favorably in a hard-to-treat metastatic osteosarcoma setting, with further trial data expected in 2026.

OS Therapies Provides OST-HER2 Metastatic Osteosarcoma Program Update and Announces Upcoming Conference Attendance

Newsfile Corp · 2 Sept 2026positive

OS Therapies announced that management, business development advisors, and its OS Animal Health subsidiary will attend several upcoming industry conferences, and provided an update on its OST-HER2 Metastatic Osteosarcoma Program. Key upcoming milestones include FDA and MHRA statistical methods meetings in September 2026, final overall survival data and BLA submission in Q4 2026, and an expected confirmatory Phase 3 trial application for Q4 2026.

Why it matters — A OSTX watcher would care because the announced regulatory milestones and conference participation indicate progress and visibility for the company's lead osteosarcoma program and its commercial plans.

OS Therapies Reports Second Quarter 2026 Financials and Provides Business and Regulatory Updates

Newsfile Corp · 17 Aug 2026neutral

OS Therapies reported its second quarter 2026 financial results and provided regulatory updates. The company announced up to $10 million in debt financing (with $5 million funded at the first closing), outlined upcoming FDA Type C and MHRA statistical methods meetings, and noted interim and final 3-year Overall Survival data timelines supporting planned BLA and Conditional MAA submissions for OST-HER2 in metastatic osteosarcoma. The U.K. also waived the Pediatric Investigation Plan (PIP) requirement for the program.

Why it matters — OSTX watchers would care because these updates clarify the company's financing, pending FDA/MHRA regulatory meetings, and data-readout timelines that underpin progress toward BLA and Conditional MAA submissions for OST-HER2.

OS Therapies Granted U.S. FDA Type C Statistical Methods Meeting to Review 2.5-Year Overall Survival Data for OST-HER2 in the Prevention or Delay of Recurrence in Fully Resected, Pulmonary Metastatic Osteosarcoma

Newsfile Corp · 13 Aug 2026positive

OS Therapies announced that the U.S. FDA granted its requested Type C Statistical Methods meeting to review 2.5-year overall survival data from the Phase 2b trial of OST-HER2 in fully resected, pulmonary metastatic osteosarcoma, with the meeting expected in mid-September 2026. The company also reported a sustained overall survival benefit between the 2-year and 2.5-year timepoints, and noted that a parallel U.K. MHRA Statistical Methods meeting was granted, with interim 3-year OS data expected in early September 2026.

Why it matters — This FDA meeting could lead to further regulatory decisions on OST-HER2 regarding the appropriate comparator arm, RMAT designation, and Rolling Review, signaling meaningful progress for OSTX's lead candidate.

FAQ

Frequently asked questions about OSTX stock

What is the OSTX stock price forecast for 2026-2027?

The 4 Wall Street analysts covering OS Therapies, Inc. have a median 12-month price target of $7.5, with estimates ranging from $6 to $13. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is OSTX stock a buy right now?

Of the 4 analysts covering OS Therapies, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks OS Therapies, Inc. 35 out of 100 across roughly 4,600 US stocks as at 11 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank OSTX?

As at 11 Sept 2026, OS Therapies, Inc. ranks 35 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (82 of 100).

Will OSTX stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts implies +346.4% from the last close, and Ticker Nerd's factor model ranks OS Therapies, Inc. 35 out of 100 as at 11 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the OSTX stock forecast for 2030?

No analyst covering OS Therapies, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for OSTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $6 to $13 over the next 12 months.

How has OSTX stock performed over the past year?

OS Therapies, Inc. returned -27.3% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does OS Therapies, Inc. do?

OS Therapies Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing treatments for osteosarcoma and other solid tumors.

What is the latest news on OSTX?

The most recent item we track (Newsfile Corp, 8 Sept 2026): "OS Therapies Achieves Statistically Significant Benefit for OST-HER2-Treated Patients in Interim 3-Year Overall Survival Analysis of Phase 2b Pulmonary Metastatic Osteosarcoma Trial". OS Therapies reported interim 3-year overall survival data from its Phase 2b pulmonary metastatic osteosarcoma trial, showing a 71.2% 3-year overall survival rate for OST-HER2-treated patients versus a 45.8% comparable combined historical control (p = 0.002). The company also received $3.15 million in VAT refunds into OS Therapies UK, Ltd., and noted that two remaining patients have monitoring visits scheduled for September and early October 2026.

Company

About OS Therapies, Inc.

OS Therapies Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing treatments for osteosarcoma and other solid tumors. The company’s current work centers on oncology programs that aim to harness the immune system against cancers expressing HER2, including its lead immunotherapy candidate OST-HER2. OS Therapies also advances an antibody-drug conjugate platform designed to support targeted cancer therapy development. Its product pipeline is directed toward high-unmet-need cancers, particularly rare bone cancers and other HER2-related solid tumors. Based in Grasonville, Maryland, OS Therapies Inc. operates within the biotechnology sector as a development-stage company focused on investigational cancer treatments and platform technologies for future clinical use.

CEO Mr. Paul A. Romness M.P.H. · 4 employees · United States · https://ostherapies.com